Back to Results

Cencora Inc (COR)

Cencora, Inc. is a common stock listing on the NYSE for a healthcare company focused on sourcing and distributing pharmaceutical products in the United States and abroad. Through its U.S. Healthcare Solutions segment, the company supplies generic and injectable medicines, over-the-counter healthcare products, home healthcare supplies and equipment, blood products, vaccines, and other specialty pharmaceuticals, while also providing pharmacy management, staffing, consulting, packaging, software, clinical trial support, commercialization services, and related data analytics. Its International Healthcare Solutions segment supports pharmaceutical wholesale and commercialization activities outside the United States and offers specialty transportation and logistics services for the biopharmaceutical industry. Formerly known as AmerisourceBergen Corporation, the company adopted the Cencora name in August 2023 and was founded in 1871. It is headquartered in Conshohocken, Pennsylvania.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-COR
$348.81
15.2% Upside
Fair
$355.58
17.4% Upside
Fair
Great
—
—
2.4
0.8%
August 5, 2026
23.2x
17.4x
0.2x
59.145 B
72.242 B
20.3%
94.6%
6.4
18.0%
61.1%
Send a message
Valuation • Fair Value

Cencora Inc (NYSE-COR) Fair Value by Valuation Model

Compare the primary fair value estimate for Cencora Inc (NYSE-COR) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$348.81

Estimated upside of 15.2% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$362.31

Discounted cash flow valuation reference.

Ben Graham Formula Value

$145.35

Classic Ben Graham valuation formula reference.

DDM Fair Value

$437.81

Dividend discount model valuation reference.

EPV Fair Value

$170.33

Earnings power value estimate.

Comps Fair Value

$335.38

Comparable-company valuation reference.

Analyst Price Target

$355.58

Analysts imply upside of 17.4%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Cencora Inc (NYSE-COR) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Cencora Inc (NYSE-COR)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

328.7 B

Current operating scale indicator.

Revenue Forecast

337.1 B

Forward revenue estimate.

EBITDA

5.3 B

Current operating profitability reference.

EBITDA Forecast

5.314 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Cencora Inc (NYSE-COR) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Cencora Inc (NYSE-COR)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.49

No elevated caution signal from this screen.

Altman Z-Score

6.4

Relatively strong balance-sheet zone.

FCF / Net Income

61.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Cencora Inc (NYSE-COR). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Cencora Inc (NYSE-COR)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 5, 2026

Days to Earnings

15

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.8%

Income yield reference.

Upcoming Dividend

2.4

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

18.0%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Cencora Inc (NYSE-COR), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Cencora Inc (NYSE-COR) Stock Forecast & Technical Outlook

Review Cencora Inc (NYSE-COR) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Cencora Inc (NYSE-COR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Cencora Inc (NYSE-COR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Cencora Inc (NYSE-COR) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Cencora Inc (NYSE-COR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Buy

The monthly technical read for Cencora Inc (NYSE-COR) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Cencora Inc (NYSE-COR)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Cencora Inc (NYSE-COR) has a Strong Buy consensus, with 8 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 8
Hold 2
Sell 0
FAQ • Fast Investor Answers

Cencora Inc (NYSE-COR) Stock FAQ

Quick answers about Cencora Inc (NYSE-COR) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$348.81
Estimated upside 15.2%
Valuation Rating
Undervalued
Estimated upside of 15.2%
Analyst Target
$355.58
Implied upside 17.4%
Financial Health
Great
Current financial-health read

The current fair value estimate for Cencora Inc (NYSE-COR) is $348.81. This implies an estimated upside of 15.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 15.2% versus the current market price.

The available analyst price target for Cencora Inc (NYSE-COR) is $355.58. The analyst target implies estimated upside of 17.4%.

The current financial health read for Cencora Inc (NYSE-COR) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Cencora Inc (NYSE-COR) is August 5, 2026.

Based on the current data, dividend yield is 0.8%, upcoming dividend amount is 2.4.

The current P/E ratio listed for Cencora Inc (NYSE-COR) is 23.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Cencora Inc is 59.145 B.

The current enterprise value listed for Cencora Inc is 72.242 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Cencora Inc is NYSE-COR, and the stock is listed on NYSE.

Cencora Inc (NYSE-COR) is listed on NYSE.

The current debt-to-total-capital ratio listed for Cencora Inc is 20.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Cencora Inc is 94.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Providers & Services Stocks on NYSE View more

Unitedhealth Group (UNH) Unitedhealth Group (UNH)
CVS Health Corp (CVS) CVS Health Corp (CVS)
McKesson Corporation (MCK) McKesson Corporation (MCK)
Elevance Health Inc (ELV) Elevance Health Inc (ELV)
HCA Holdings Inc (HCA) HCA Holdings Inc (HCA)
Cigna Corp (CI) Cigna Corp (CI)
Cardinal Health Inc (CAH) Cardinal Health Inc (CAH)
Humana Inc (HUM) Humana Inc (HUM)
Centene Corp (CNC) Centene Corp (CNC)
Labcorp Holdings Inc (LH) Labcorp Holdings Inc (LH)
Quest Diagnostics Incorporated (DGX) Quest Diagnostics Incorporated (DGX)
Tenet Healthcare Corporation (THC) Tenet Healthcare Corporation (THC)
DaVita HealthCare Partners Inc (DVA) DaVita HealthCare Partners Inc (DVA)
Fresenius Medical Care Corporation (FMS) Fresenius Medical Care Corporation (FMS)
Molina Healthcare Inc (MOH) Molina Healthcare Inc (MOH)
Encompass Health Corp (EHC) Encompass Health Corp (EHC)
Universal Health Services Inc (UHS) Universal Health Services Inc (UHS)
Hims Hers Health Inc (HIMS) Hims Hers Health Inc (HIMS)
PACS Group Inc (PACS) PACS Group Inc (PACS)
Chemed Corp (CHE) Chemed Corp (CHE)
Hinge Health Inc (HNGE) Hinge Health Inc (HNGE)
Concentra Group Holdings Parent Inc (CON) Concentra Group Holdings Parent Inc (CON)
Brookdale Senior Living Inc (BKD) Brookdale Senior Living Inc (BKD)
National HealthCare Corporation (NHC) National HealthCare Corporation (NHC)